SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Lyell Immunopharma's S-3 shelf registration (File No

Lyell Immunopharma, Inc. · EFFECT filed Jul 22, 2026 at 00:15 ET

At the news

NEUTRALIMPACT 4/10

EFFECT filed Jul 22, 2026 at 00:15 ET

Lyell Immunopharma's S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026. This allows selling stockholders to resell up to 1,952,360 shares of common stock acquired in a March 2026 private placement. The company receives no proceeds from these sales, but the effectiveness introduces a potential overhang of ~1.95M shares that can be sold into the market at any time, representing approximately 0.6% of the current market cap of $321M, a modest but real dilution risk for a pre-revenue biotech with limited liquidity.

  • S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026.
  • Registration covers resale of 1,952,360 shares of common stock by selling stockholders.
  • Selling stockholders include institutional investors ARCH Venture Fund, Gates Frontier, and Explore Investments.
  • Lyell Immunopharma will not receive any proceeds from these share sales.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access